Skip to content
Review Open access

Host genetic determinants of HTLV-1 infection outcomes

Aug 2026 · Immunologic research · Vol 74 · 0 citations · 82 references
Medicine

TL;DR

Evidence is synthesized demonstrating how inherited host genetic variation and acquired somatic alterations influence HTLV infection outcomes that support a continuum model in which inherited host genetics condition viral persistence and immune pressure, while acquired genetic and epigenetic lesions determine disease phenotype and severity.

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) is a persistent human retrovirus associated with severe outcomes, most notably adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite lifelong infection, only a minority of carriers develop clinical disease, highlighting a decisive role for host genetic background in shaping viral control, immune activation, and pathogenic progression. This mini-review synthesizes evidence demonstrating how inherited host genetic variation and acquired somatic alterations influence HTLV infection outcomes. Polymorphisms in HLA class I and II genes critically modulate antigen presentation and cytotoxic or helper T-cell responses, thereby regulating proviral load and immune-mediated tissue damage. Variants in cytokine, chemokine, and innate restriction factor genes, including IL28B, IL8, TRIM5α, and APOBEC family members, further influence viral persistence and inflammatory risk. In parallel, accumulating somatic mutations in TP53, CCR4, JAK/STAT components, NOTCH1, and epigenetic regulators such as TET2 and KMT2D drive clonal expansion, genomic instability, and malignant transformation in ATLL. Together, these data support a continuum model in which inherited host genetics condition viral persistence and immune pressure, while acquired genetic and epigenetic lesions determine disease phenotype and severity. Integrating host genomics with viral genetics and clonal evolution analyses will be essential for developing predictive biomarkers and personalized therapeutic strategies for HTLV-associated diseases.

Read PDF

Similar papers

Review Oct 2026

Targeting HTLV-1 Tax: Towards a Therapeutic Strategy for HTLV-1- Associated Diseases.

Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that belongs to the family Retroviridae and the genus Deltaretrovirus. HTLV-1 infection is linked to acute and chronic illnesses, including adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), an...

Sudipto Roy, Sayak Sanyal, Manish Dwivedi et al. · 0 citations
Review Open access Oct 2026

HIV-1 Vpr: a multifunctional accessory protein with potential contributions to AIDS pathogenesis and persistence

Human immunodeficiency virus type 1 (HIV-1) infection can progress to acquired immune deficiency syndrome (AIDS), which is characterized by a rapid decline in CD4+ T lymphocyte counts, severe impairment of host immune competence, and recurrent opportunistic infections. Over the past four decades, HIV infection has rema...

Juan Du, Qing-Chen Li, Shao-Hua Wang et al. · 0 citations
Review Open access Oct 2026

Primer: Human T-cell leukemia virus type 1 (HTLV-1)

ABSTRACT The human T-cell leukemia virus HTLV-1—also known as human T-lymphotropic virus type 1—was the first human retrovirus discovered. Unlike HIV-1, it has been present in humans for tens of thousands of years, and in consequence HTLV-1 is exquisitely adapted to persist in the individual host. Its life history ther...

C. Bangham, Masao Matsuoka · 0 citations
Open access Nov 2026

CD8+ regulatory T cells limit immunopathology but impair viral clearance in Hantaan virus infection.

In hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), virus-specific CD8+ T cells mediate both viral clearance and immunopathology. Here, we characterized a CD8+ regulatory T cell (Treg) subset restricted by HLA-E (and its murine ortholog Qa-1) in HFRS patients and in a murine HTNV infection m...

K. Tang, Xiao-Yue Xu, He Liu et al. · 0 citations
Open access 2025

The broad spectrum of immune dysregulation: clinical cases

INTRODUCTION: Inborn errors of immunity are classified according to the many possible genetic defects, and 25% manifest as immune dysregulation. CTLA-4 (cytotoxic T-lymphocyte antigen 4) haploinsufficiency has been associated with variable clinical presentations, ranging from asymptomatic carriers (30%) to patients wit...

João Pedro Araujo da Costa Aires, Paula Christina Cavallini de Melo Maricondi, A. Grumach et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.